March 8, 2021

Now available XTANDI® tablets

XTANDI® (enzalutamide) is indicated as a treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel, and treatment of castration-resistant prostate cancer (CRPC), including nonmetastatic CRPC.